Jaguar Health, Inc. Share Price & Technical Analysis
JAGX · $3.92 (-0.51%)
Healthcare / Biotechnology
$3.92
-0.51%
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. It…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-59% return in May, -34% avg return in past 3 year May month.
-161% return in 2026, -143% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -29% | 31% | -58% | -46% | -59% | – | – | – | – | – | – | – | -161% |
| 25 | -16% | -32% | -69% | 149% | -63% | -42% | -18% | -19% | 39% | -16% | -33% | -29% | -148% |
| 24 | -32% | -41% | 48% | 156% | -69% | -14% | -65% | -7% | 17% | -19% | -3% | -1% | -29% |
| 23 | -31% | -59% | -67% | -22% | 29% | -22% | 22% | -41% | -35% | 31% | 1% | -58% | -252% |
| 22 | -22% | -45% | 52% | -34% | -19% | -21% | -13% | -10% | -34% | -11% | -6% | -33% | -196% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.18M
P/E ratio
—
52W high
$241.5
52W low
$2.53
Volume
44,651
Beta
0.03
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Jaguar Health, Inc. share price today?
- Jaguar Health, Inc. (JAGX) last traded around $3.92 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does JAGX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for JAGX. Download the app for real-time alerts.
- How can I analyze Jaguar Health, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.